Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: PTK6

Gene summary for PTK6

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

PTK6

Gene ID

5753

Gene nameprotein tyrosine kinase 6
Gene AliasBRK
Cytomap20q13.33
Gene Typeprotein-coding
GO ID

GO:0001932

UniProtAcc

Q13882


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
5753PTK6HTA11_2487_2000001011HumanColorectumSER3.00e-248.09e-01-0.1808
5753PTK6HTA11_1938_2000001011HumanColorectumAD3.53e-043.62e-01-0.0811
5753PTK6HTA11_78_2000001011HumanColorectumAD1.60e-043.62e-01-0.1088
5753PTK6HTA11_347_2000001011HumanColorectumAD3.97e-297.29e-01-0.1954
5753PTK6HTA11_411_2000001011HumanColorectumSER3.46e-081.14e+00-0.2602
5753PTK6HTA11_2112_2000001011HumanColorectumSER4.86e-098.82e-01-0.2196
5753PTK6HTA11_3361_2000001011HumanColorectumAD2.95e-105.49e-01-0.1207
5753PTK6HTA11_83_2000001011HumanColorectumSER6.18e-187.71e-01-0.1526
5753PTK6HTA11_696_2000001011HumanColorectumAD3.99e-186.83e-01-0.1464
5753PTK6HTA11_866_2000001011HumanColorectumAD9.50e-103.54e-01-0.1001
5753PTK6HTA11_1391_2000001011HumanColorectumAD1.40e-146.20e-01-0.059
5753PTK6HTA11_2992_2000001011HumanColorectumSER1.03e-026.66e-01-0.1706
5753PTK6HTA11_5212_2000001011HumanColorectumAD8.05e-076.62e-01-0.2061
5753PTK6HTA11_10623_2000001011HumanColorectumAD1.41e-024.61e-01-0.0177
5753PTK6HTA11_10711_2000001011HumanColorectumAD2.00e-032.77e-010.0338
5753PTK6HTA11_7696_3000711011HumanColorectumAD7.73e-052.70e-010.0674
5753PTK6HTA11_99999971662_82457HumanColorectumMSS1.75e-197.74e-010.3859
5753PTK6HTA11_99999974143_84620HumanColorectumMSS9.29e-082.85e-010.3005
5753PTK6A015-C-202HumanColorectumFAP1.38e-022.45e-01-0.0849
5753PTK6LZE4THumanEsophagusESCC3.46e-081.81e-010.0811
Page: 1 2 3 4 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:00457872ColorectumFAPpositive regulation of cell cycle66/2622313/187233.66e-044.63e-0366
GO:00610992ColorectumFAPnegative regulation of protein tyrosine kinase activity11/262231/187232.26e-031.84e-0211
GO:0048565ColorectumFAPdigestive tract development29/2622127/187234.75e-033.20e-0229
GO:0055123ColorectumFAPdigestive system development30/2622137/187237.75e-034.60e-0230
GO:0010563111EsophagusESCCnegative regulation of phosphorus metabolic process274/8552442/187232.32e-129.41e-11274
GO:0045936111EsophagusESCCnegative regulation of phosphate metabolic process273/8552441/187233.18e-121.25e-10273
GO:0051348111EsophagusESCCnegative regulation of transferase activity177/8552268/187231.08e-114.00e-10177
GO:0042326111EsophagusESCCnegative regulation of phosphorylation237/8552385/187231.86e-105.33e-09237
GO:0001933111EsophagusESCCnegative regulation of protein phosphorylation213/8552342/187233.54e-109.76e-09213
GO:004578710EsophagusESCCpositive regulation of cell cycle196/8552313/187239.27e-102.24e-08196
GO:003367319EsophagusESCCnegative regulation of kinase activity154/8552237/187231.38e-093.27e-08154
GO:000646920EsophagusESCCnegative regulation of protein kinase activity140/8552212/187231.53e-093.56e-08140
GO:003812718EsophagusESCCERBB signaling pathway82/8552121/187237.23e-079.40e-0682
GO:004677710EsophagusESCCprotein autophosphorylation138/8552227/187232.98e-063.38e-05138
GO:000717318EsophagusESCCepidermal growth factor receptor signaling pathway73/8552108/187233.36e-063.73e-0573
GO:00459267EsophagusESCCnegative regulation of growth148/8552249/187237.88e-067.73e-05148
GO:003134616EsophagusESCCpositive regulation of cell projection organization201/8552353/187231.19e-051.11e-04201
GO:190118413EsophagusESCCregulation of ERBB signaling pathway54/855279/187233.81e-053.08e-0454
GO:00507322EsophagusESCCnegative regulation of peptidyl-tyrosine phosphorylation42/855259/187236.35e-054.84e-0442
GO:00420588EsophagusESCCregulation of epidermal growth factor receptor signaling pathway50/855273/187236.75e-055.12e-0450
Page: 1 2 3 4 5 6 7 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
PTK6SNVMissense_Mutationc.119N>Cp.Lys40Thrp.K40TQ13882protein_codingtolerated(0.17)possibly_damaging(0.661)TCGA-AA-3492-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
PTK6SNVMissense_Mutationrs770065818c.832N>Ap.Asp278Asnp.D278NQ13882protein_codingtolerated(0.43)benign(0.001)TCGA-AZ-6601-01Colorectumcolon adenocarcinomaMale>=65I/IIUnknownUnknownPD
PTK6SNVMissense_Mutationc.802G>Ap.Ala268Thrp.A268TQ13882protein_codingtolerated(0.26)benign(0.011)TCGA-CK-5913-01Colorectumcolon adenocarcinomaFemale<65I/IIUnknownUnknownSD
PTK6SNVMissense_Mutationc.340T>Cp.Tyr114Hisp.Y114HQ13882protein_codingtolerated(0.06)benign(0.397)TCGA-EI-6882-01Colorectumrectum adenocarcinomaMale<65I/IIUnknownUnknownSD
PTK6SNVMissense_Mutationrs761742593c.1313N>Ap.Arg438Glnp.R438QQ13882protein_codingtolerated(1)benign(0.003)TCGA-A5-A0G1-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
PTK6SNVMissense_Mutationrs200723492c.619N>Ap.Glu207Lysp.E207KQ13882protein_codingtolerated(0.1)benign(0.135)TCGA-A5-A2K5-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
PTK6SNVMissense_Mutationrs757318592c.109N>Ap.Val37Metp.V37MQ13882protein_codingdeleterious(0)probably_damaging(0.954)TCGA-AJ-A3OL-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycarboplatinPD
PTK6SNVMissense_Mutationnovelc.638G>Ap.Arg213Glnp.R213QQ13882protein_codingtolerated(0.55)benign(0.001)TCGA-AP-A059-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
PTK6SNVMissense_Mutationnovelc.1137N>Tp.Glu379Aspp.E379DQ13882protein_codingdeleterious(0)probably_damaging(0.998)TCGA-AP-A0LM-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycisplatinSD
PTK6SNVMissense_Mutationnovelc.1222N>Cp.Cys408Argp.C408RQ13882protein_codingtolerated(0.45)benign(0.007)TCGA-AP-A1DK-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
Page: 1 2 3 4 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
5753PTK6DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, TYROSINE KINASE, ENZYMEinhibitor249565866
5753PTK6DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, TYROSINE KINASE, ENZYMEinhibitor315661136
5753PTK6DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, TYROSINE KINASE, ENZYMETAE-684TAE-684
5753PTK6DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, TYROSINE KINASE, ENZYMEOSI-632OSI-632
5753PTK6DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, TYROSINE KINASE, ENZYMECEDIRANIBCEDIRANIB
5753PTK6DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, TYROSINE KINASE, ENZYMESB-202190SB-20219022951114
5753PTK6DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, TYROSINE KINASE, ENZYMEinhibitorCHEMBL24828VANDETANIB
5753PTK6DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, TYROSINE KINASE, ENZYMEDASATINIBDASATINIB
5753PTK6DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, TYROSINE KINASE, ENZYMETAMATINIBR-406
5753PTK6DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, TYROSINE KINASE, ENZYMEISIS-CRP
Page: 1 2